Citius Pharmaceuticals, Inc.

Public biopharma companies usually spend the week before the J.P. Morgan Healthcare Conference announcing new financings, partnerships and sometimes data so that they have compelling milestones to dis

Lexeo Therapeutics Inc. became the 20th biopharma to launch an initial public offering in the US on 2 November when it sold 9.09 million shares at $11 each to gross $100m in its late-night public mar

After approving seven novel agents in June, the US FDA may be able to relax a little in July. The coming month features a handful of novel agents, new formulations, and an OTC product among fewer than

The US FDA’s Center for Drug Evaluation and Research cleared two new molecular entities in the last days of September, both for rare diseases – intrahepatic cholangiocarcinoma for Taiho Pharmaceutica